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Introduction: Pulmonary hypertension can be associated with decreased functional capacity
and poor prognosis in patients with parenchymal lung diseases (PLD). Yet, little attention
has been given to current beliefs and practice patterns.
Methods: An 18-question survey was submitted electronically to members of four Networks of
the American College of Chest Physicians.
Results: Analyzable responses were received from 453 physicians. Most (95%) respondents
reported testing for PH in patients with PLD using transthoracic echocardiography (TTE) or
right-heart catheterization (RHC) and believed that PH could occur in the absence of severe
compromise in pulmonary function (70%) and hypoxemia (50%). Approximately 30% of
physicians reported not performing RHC to confirm a diagnosis of PH before initiating therapy.
Most respondents (92%) felt that medical therapy was effective and the medication of first
choice was either bosentan or sildenafil. Most respondents believed that treating PH in these
patients improves quality of life (63%) and dyspnea (67%), but were less sure about the impact
on functional capacity and survival.
Conclusions: Approximately 30% of physicians do not perform RHC to confirm this diagnosis
prior to initiating therapy. Despite relatively little supportive evidence, most physicians treat
with vasoactive medications and believe that medical therapy confers benefit.
ª 2010 Published by Elsevier Ltd.445 2610; fax: þ1 216 445 1878.
.A. Minai).
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Pulmonary hypertension (PH) is defined by the presence of
a resting mean pulmonary arterial pressure (mPAP)
25 mmHg.1e3 PH may occur as an ‘idiopathic’ disease of
the pulmonary vasculature or may be the result of under-
lying cardiac and/or pulmonary diseases.1e3 In fact, PH
associated with underlying pulmonary diseases is far more
common than idiopathic PH.4,5 Several reports6e10 in
patients with various forms of advanced parenchymal lung
diseases (PLD) have shown a high prevalence of PH. These
and other studies have also indicated that the occurrence
of PH in patients with advanced PLD (PLD-PH) is associated
with increased functional limitation and mortality.6,8,11e13
It is, however, less clear whether pharmacotherapy for
PLD-PH results in significant functional or survival benefit.
No prospective, randomized trials evaluating this approach
have yet been published and the literature on the subject
remains largely limited to case series or case reports.14e17
Several recent reports have highlighted important limita-
tions in benefit obtained either due to continued progres-
sion of the underlying PLD or worsening of associated
hypoxemia. In addition, consensus guidelines only address
treatment of patients with pulmonary arterial hypertension
(PAH) and do not address PLD-PH.5 Given this lack of
objective evidence and the continued need to provide
relief to patients, we conducted a survey to assess beliefs
of physicians involved in caring for these patients regarding
epidemiology, diagnosis, and treatment approaches.
Methods
Survey creation
Survey components were initially identified by searching
MEDLINE and EMBASE from 1998-2008 using the following key
words: COPD, interstitial lung disease, pulmonary fibrosis,
pulmonary hypertension, parenchymal lung disease. Identi-
fied references were reviewed to determine medications
commonly used for PLD-PH and any reports on therapy
including randomized trials, cohort studies, case reports or
any guidelines or treatment algorithms. The survey was
structured into three sections (Appendix 1). The first section
focused on demographic and epidemiologic data, the second
characterized thediagnostic approach, and the third focused
onbeliefs regarding treatment and its efficacy.Adraft survey
was then distributed to clinicians with a known interest and
expertise in PH (i.e., all coauthors). These experts were
asked to comment on the relevance of each survey item and
the clarity of each response option. The feedback and results
of this pre-pilot surveywere used to further refine the survey
instrument. The final survey instrument was further exam-
ined for face validity, content validity, internal consistency,
and construct validity by an expert with formal training in
survey development.
Survey population and administration
The survey was approved by the Steering Committee of the
Pulmonary Vascular Disease Network of the American
College of Chest Physicians (ACCP) and was submitted tothe members of four Networks: the Pulmonary Vascular
Disease, Interstitial and Diffuse Lung Disease, Cardiovas-
cular Disease and Hypertension, and the Clinical Pulmonary
Medicine Networks. To maximize response, the survey was
administered electronically by the ACCP 3 times biweekly
between January and March 2008. The survey was accom-
panied by a brief introduction of the purpose of the survey.
All responses were anonymous, respondents were allowed
a partial response, and only one response per respondent
was permitted.
Data analysis
Individual survey responses were compiled for overall
analysis. Categorical measures were summarized using
frequencies and percentages. Subsequently, responses
were stratified by physician respondents’ characterizing
themselves as being in private practice [Group 1] vs. those
working in academic medical centers or university hospitals
[Group 2]. Categorical measures were summarized using
frequencies and percentages. Pearson Chi-square test was
used unless listed otherwise. Values of p< 0.05 were
considered statistically significant. SAS 9.1.3 software (SAS
Institute, Cary, NC) was used for all analyses.
Results
Characteristics of survey respondents
The survey was sent to a total of 2941 physicians; 20 (0.6%)
were not deliverable and 453 (16%) responded. Of these, 426
(94%)werepulmonologists, 8 (1.7%)were cardiologists, 1was
a rheumatologist, and 21 (4.6%) did not identify their
specialty. Among pulmonologists, 219 (51.5%)were in private
practice [Group 1] and 207 (48.5%) worked in an academic
setting (Group 2). Sixty-six percent of respondents saw <6
patients of PLD-PH per month and 34% saw 6.
PH prevalence, significance, and hemodynamic
characteristics
Twenty-two percent of respondents felt that 10% patients
with COPD in their practice had PH whereas only 5% of
respondents felt this was true of patients with IPF (Fig. 1).
Sixteen percent of the respondents felt that PH occurred in
30% patients with COPD, whereas 40% of respondents felt
>30% of patients with IPF had PH. Ten percent of respon-
dents felt that >50% of patients with IPF had PH.
Forty eight percent of respondents thought that patients
with PLD-PH have a normal cardiac index (48%), and most
thought that right atrial pressure (73%) and pulmonary
vascular resistance (84%) are elevated, and that wedge
pressure is normal (76%). Six percent of respondents felt
that severe PH did not occur in association with PLD, 70%
felt that severe PH could be seen in PLD patients with mild
or moderate lung disease, and 50% felt severe PH could
occur in the absence of hypoxemia (Fig. 2). Most respon-
dents were of the opinion that the presence of PH was an
indicator of poor prognosis (Fig. 3), and an important
determinant of functional limitation, dyspnea, and hypox-
emia in patients with PLD.
Figure 1 Perception of respondents regarding the preva-
lence of PH in patients with PLD.
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Five percent of respondents do not screen PLD patients for
PH (Fig. 4) and 18% of respondents screen all PLD patients
for PH. The most common reasons for screening were
unexplained shortness of breath, abnormally low diffusion
capacity for carbon monoxide, and associated hypoxemia.
The tests most commonly used for screening of PH
included right-heart catheterization (RHC; 62%) and trans-
thoracic echocardiography (TTE; 35.6%). Only a minority
found spirometry, diffusion capacity for carbon monoxide,
PaO2, brain natriuretic peptide measurement, or radio-
graphic imaging useful in screening for PH.
Regarding the need for RHC, 33% of respondents felt that
a RHC was not required to make a diagnosis of PH in
a patient suspected to have PH by TTE. In the presence of
right ventricular dilatation on TTE, 55% of physicians per-
formed RHC if the right ventricular systolic pressure (RVSP)
exceeded 40 mmHg and 72% performed RHC if the RVSP
exceeded 45 mmHg (Table 1). In the absence of right
ventricular dilatation, only 19% performed a RHC with
a RVSP 40 mmHg and 62% performed a RHC only if the
RVSP was >50 mmHg.Figure 2 Perception of respondents regardingTreatment of PH in patients with PLD
Most respondents (92%) felt that currently available treat-
ment modalities are effective in treating PLD-PH. Sixteen
percent of respondents treated all patients with PLD-PH
with vasoactive medications, whereas others treated
patients in selected situations including: significant func-
tional limitation (40%), severe PH (34%), PH out of propor-
tion to the degree of compromise in pulmonary function
(40%), and persistent PH despite oxygen supplementation
(37%). Only 15% of respondents did not treat any patients
with IPF-associated PH, while 38% of respondents treated
11% or more of patients, and 6% treated >50% of patients
with IPF-associated PH with vasoactive medications
(Fig. 5). In contrast, a much higher proportion of respon-
dents did not treat PH related to COPD (36%), sarcoidosis
(30%), and cystic fibrosis (59%) with vasoactive medications.
Seventy one percent of respondents felt that oxygen
therapy was the most effective treatment of PLD-PH
(Fig. 6). Parenteral prostanoids, endothelin receptor
antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5
inh), and inhaled prostanoids were all felt to be effective
modalities in treating PLD-PH patients. The least effective
forms of treatment were felt to be immunosuppressive
agents (such as azathioprine, cyclosporine, and imatinib),
systemic corticosteroids, and calcium channel antagonists.
Ninety percent of physicians reported treating patients
with supplemental oxygen in the case of desaturation to
<90% during exertion or sleep. However, only 50% of
respondents performed nocturnal oximetry studies to look
for nocturnal desaturation in these patients.
First-line therapy was bosentan or sildenafil for PH
associated with IPF or sarcoidosis and sildenafil for PH
associated with COPD (Fig. 7). A significant proportion of
respondents felt that PH-specific vasoactive therapy
improved six-minute walk distance (44%), quality of life
(64%), and dyspnea (67%) among patients with PLD.
However, only a minority (24%) felt that such therapy
resulted in improved survival. Thirty three percent of
respondents felt that an increase in 6MWD and functional
capacity, even in the presence of worsening hypoxemia on
PH-specific vasoactive therapy, represented an adequate
therapeutic response; 33% disagreed with this statement,
and 34% were unsure. Surprisingly, only 12% of respondents
were concerned about the potential for worseningthe occurrence of PH in patients with PLD.
Figure 3 Respondents’ perceptions about the significance of PH in patients with PLD.
Figure 4 Screening for PH in patients with PLD.
Table 1 Results in response to the question: at what level
of echocardiographic abnormality do you ask your patient to
undergo right-sided heart catheterization if there is no
evidence of left-sided cardiac dysfunction?
Right ventricular
systolic pressure
Normal RV
(cumulative %
respondents)
Dilated or
dysfunctional
RV (cumulative
% respondents)
>35 mmHg 7 29
>40 mmHg 19.5 55
>45 mmHg 38 72.5
>50 mmHg 66 88.5
>55 mmHg 81 95
>60 mmHg 100 100
744 O.A. Minai et al.hypoxemia with the use of parenteral prostanoids in
patients with PLD-PH.
The most useful methods for monitoring treatment
response (in descending order of perceived accuracy) were:
RHC followed by TTE, WHO/NYHA functional class assess-
ment, 6MWD, and brain natriuretic peptide levels.
Comparing respondents by location of practice
Overall, there was a remarkable degree of concordance in
practice patterns between the physicians in private prac-
tice (Group 1) and those in academic institutions (Group 2).
Approximately 37% of respondents in Group 1 and 27% in
Group 2 felt that a RHC was not needed to make a diagnosis
of PH prior to initiating therapy. Physicians in Group 2 were
more likely to view pulmonary rehabilitation as important
in the management of their patients (32% vs. 19%; pZ 0.02)
and physicians in Group 1 were more likely to perform
nocturnal oximetry studies (49% vs. 39%; pZ 0.04). A
significant proportion of physicians in both groups (30% in
Group 1 and 40% in Group 2) did not provide oxygen
supplementation to their patients if they desaturated to
<90% during sleep. Regarding treatment of PLD-PH,physicians in Group 2 were more likely to only treat
patients with ‘‘PH out of proportion to the degree of lung
dysfunction’’ (pZ 0.01) or ‘‘severe PH’’ (pZ 0.09)
compared to Group 1. Choice of first-line agents was not
significantly different between the groups, irrespective of
Figure 5 Percentage of patients with PLD-associated PH receiving PH-specific vasoactive therapy.
Pulmonary hypertension in lung diseases 745underlying disease. In terms of treatment response, more
physicians in Group 1 felt that vasoactive therapy signifi-
cantly improved 6MWD, functional capacity (48% vs. 37%;
pZ 0.01), and survival (25% vs. 18%; pZ 0.09) compared to
physicians in Group 2.Discussion
This study represents the first large-scale assessment of
beliefs and self-reported clinical practice patterns of
physicians caring for patients with PLD-PH. This survey was
able to capture a large sample of pulmonary specialists in
academic centers as well as in private practice and thus
includes perspectives from both settings. The salient find-
ings of our study are as follows: (1) physicians believe that
PH occurs in a significant proportion of patients with PLD
and that PH in these patients is an indicator of poor prog-
nosis and significant functional limitation; (2) despite itsFigure 6 Perceptions regarding the most and least efficacious o
thelin receptor antagonist; PDE, phosphodiesterase-5 inhibitor;
analogue; PR, pulmonary rehabilitation; AZA/cyclo, azathioprine/c
channel blockers.limitations, TTE remains the most commonly used screening
test for PH in this setting; (3) approximately 30% of physi-
cians in practice do not perform RHC to confirm the diag-
nosis of PH prior to initiating therapy; and (4) despite
relatively little supportive evidence, most physicians treat
these patients with vasoactive medications and believe
that these medications can confer significant benefit.
Notably,most respondents felt that>10% of patients with
various forms of PLD have associated PH.We suspect that this
perceptionmay be colored by the fact thatmost publications
relating to this subject have included patients being evalu-
ated for surgical procedures such as lung volume reduction
surgery and/or lung transplantation.6,8,18,19 By definition,
these patients have more advanced PLD and are therefore
more likely to have significant hypoxemia and PH. The true
prevalence of PH in an unselected sample of patients with
any form of PLD remains unknown but is likely to be lower
than that in a subgroup of patients with advanced PLD.
Another point of interest is that, in contrast to availableptions in treating PLD-associated PH. O2, oxygen; ERA, endo-
PP, parenteral prostanoid analogue; IP, inhaled prostanoid
yclophosphamide; SCS, systemic corticosteroids; CCB, calcium
Figure 7 Choice of first-line agent in treating patients with PLD-associated PH once a decision to treat has been made. ERA,
endothelin receptor antagonist; PDE, phosphodiesterase-5 inhibitor; PP, parenteral prostanoid analogue; IP, inhaled prostanoid
analogue.
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patients with IPF than in any other form of PLD.
Most respondents appreciated that severe PH can occur
in patients with PLD including, on occasion, in those with
relatively mild to moderate PLD. In addition, the survey
respondents typically knew that the presence of PH is an
indicator of poor functional capacity and shortened survival
in these patients. These findings have been extensively
reported in the literature in association with IPF, COPD, and
sarcoidosis.13,20,21 On the other hand, approximately 20% of
respondents did not indicate that PH is an important
determinant of gas exchange, functional limitation, and
survival in these patients.
Most survey respondents reported using TTE to screen
for PH in patients with PLD despite numerous studies that
have highlighted the significant limitations of TTE in this
regard.2,16,19,21 Nonetheless, TTE remains the most
commonly used method to screen for PH due to its non-
invasiveness, widespread availability, and relatively low
cost. Some survey respondents reported using pulmonary
function tests, PaO2, and brain natriuretic peptide levels to
diagnose PH. Several studies have shown that the severity
of pulmonary function abnormality (including diffusing
capacity) and PaO2 correlate loosely with the presence or
absence of PH6e8,18; however, their value in screening for
PH remains unclear.
One of the most surprising findings of this survey was
that approximately 30% of physicians from both groups
were not using RHC to confirm or refute the diagnosis of
PLD-PH patients before initiating therapy. We find this
perplexing in view of the extensive literature regarding the
limitations of non-invasive diagnostic methods, including
TTE, in making a diagnosis of PH in these patients.6,18e22
Establishing the correct diagnosis in PH is extremely
important because its presence has significant prognostic
implications. In addition, vasoactive medications are
expensive and may have significant side effects. Although,
the role of RHC in PLD has not been well-defined, we
believe that it is an important diagnostic tool in these
patients and should always be performed before any vaso-
active therapy is considered.
Most respondents felt that oxygen supplementation is
the most effective treatment for PLD-PH. In severalstudies, a low diffusion capacity for carbon monoxide and
the presence of hypoxemia were the abnormalities most
closely associated with the presence of PH.21 Hypoxic
pulmonary vasoconstriction is also felt to play an important
role in the development of PH in patients with PLD; the
duration and severity of hypoxemia required remain poorly
defined and might vary on a case by case basis. Minai et al.
reported that 70% of patients with PAH alone have
nocturnal hypoxemia23 and among these patients, evalu-
ating for exertional hypoxemia was not a good screening
test for the presence of nocturnal hypoxemia. Current
recommendations suggest providing patients with supple-
mental oxygen to keep oxygen saturation >90% during sleep
or with activity.24 Most physicians in our survey reportedly
followed these recommendations; still, only 50% of
respondents reported performing nocturnal oximetry
testing on patients with PLD-PH.
In contrast to available data, 92% of respondents felt
that currently available treatments were effective in
treating PLD-PH. To our knowledge, none of the currently
available treatment modalities has been sufficiently tested
in patients with PLD-PH to establish efficacy. Recent case
series have pointed to short-term improvement in func-
tional capacity with vasoactive medications,14e16 but none
report a sustained benefit. Perhaps the strongest case for
an effective intervention can be made for oxygen supple-
mentation in COPD-associated PH, for which some stud-
ies25e27 have suggested stabilization or improvement in
pulmonary hemodynamics. Overall, we submit that the
benefits of oxygen supplementation in the treatment of
PLD-PH requires further study.
Notwithstanding the lack of evidence for efficacy,
physicians reported treating a significant proportion of
patients with PLD-PH with various vasoactive medications.
Oral vasoactive agents remained those most commonly
used, likely due to ease of availability, cost, and the
concern for worsening hypoxemia from the use of paren-
teral prostanoid analogues.17,28 Most respondents only
treated selected subgroups of patients with PLD-PH. These
groups included those with significant functional limitation,
severe PH, PH out of proportion to the degree of compro-
mise in pulmonary function, and persistent PH despite
oxygen supplementation. However, these subgroups remain
Pulmonary hypertension in lung diseases 747very poorly defined in the literature and therefore subject
to personal bias. Such subjective patient selection reflects
a lack of evidence in the field and the need for more
studies, some of which are currently underway and may
help provide clarity going forward.
Several limitations of our study warrant comment. First,
notwithstanding the large absolute number of respondents
(NZ 453), we cannot exclude the possibility of a sample
bias in that only 16% of all physicians who were approached
responded. Still, this response rate is typical of on-line
surveys29 and systematic biases between responders and
non-responders have not been reported. Also, the survey
was only sent to selected networks of the ACCP thought to
have an interest in the subject matter and therefore,
results might not be representative of the community of
general pulmonologists. Furthermore, as neither cardiolo-
gists nor rheumatologists were represented in the survey,
our results may not apply to them.
In summary, respondents to this survey of ACCP
members regarding the diagnosis and management of PH
associated with PLD indicated that PH is common in PLD,
that they did not always perform RHC to confirm the diag-
nosis before therapy was initiated, and that therapy with
vasoactive medications confers benefit. To the extent that
these impressions are discordant with data from the avail-
able literature, our findings point out the need for further
research and for better methods to disseminate known
findings to the clinical community.
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